Offer - Urjas Oil for just ₹ 1 X
Olmezest Beta 25 Tablet ER is a prescription medicine that is available as a Tablet. Olmezest Beta 25 Tablet ER also has some secondary and off-label uses. These are listed below.
The right dosage of Olmezest Beta 25 Tablet ER depends on the age, gender, and medical history of the patient. Individual symptoms and route of administration also determines the right dosage. For detailed information on this, read through the dosage section.
Common side effects of Olmezest Beta 25 Tablet ER include Upper respiratory tract infection, Slow heart rate (pulse). Apart from the aforementioned side effects, Olmezest Beta 25 Tablet ER can also lead to other problems, which have been listed below. These side effects of Olmezest Beta 25 Tablet ER are usually temporary and subside with the completion of treatment. Please speak with your doctor if these side effects worsen or persist for a longer duration.
Furthermore, you should know that effect of Olmezest Beta 25 Tablet ER is Severe for pregnant women and Mild for women who are breastfeeding. Further, the section on Olmezest Beta 25 Tablet ER related warnings talks about Olmezest Beta 25 Tablet ER's effects on the liver, heart and kidney.
Individuals suffering from medical conditions like Bradycardia (Slow Heart Rate), Low Blood Pressure (Hypotension), Bradycardia (Slow Heart Rate) must refrain from the use of Olmezest Beta 25 Tablet ER since this can cause severe adverse effects. Some other conditions that can be affected by Olmezest Beta 25 Tablet ER are listed in the contraindications section below.
Additionally, Olmezest Beta 25 Tablet ER may also adversely react with other medicines. Refer to the list below for further details.
In addition to the above precautions for Olmezest Beta 25 Tablet ER, it is important to know that it is not safe while driving, and is not habit-forming.
Olmezest Beta 25 Tablet ER is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
Is the use of Olmezest Beta 25 Tablet ER safe for pregnant women?
Olmezest Beta shows severe side effect on pregnant women. For this reason, pregnant women should only take it after taking medical advice.
Is the use of Olmezest Beta 25 Tablet ER safe during breastfeeding?
Olmezest Beta has been seen to have minimal side effects on breastfeeding women.
What is the effect of Olmezest Beta 25 Tablet ER on the Kidneys?
Olmezest Beta is completely safe for kidneys.
What is the effect of Olmezest Beta 25 Tablet ER on the Liver?
Side effects of Olmezest Beta rarely affect the liver.
What is the effect of Olmezest Beta 25 Tablet ER on the Heart?
Olmezest Beta may have mild side effects on the heart. Most people will never see any effect on the heart.
Olmezest Beta 25 Tablet ER should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Olmezest Beta 25 Tablet ER unless your doctor advises you to do so -
Is this Olmezest Beta 25 Tablet ER habit forming or addictive?
No, there is no any evidence that Olmezest Beta 25 Tablet ER is addictive.
Interaction between Food and Olmezest Beta 25 Tablet ER
Taking Olmezest Beta 25 Tablet ER with some specific foods may delay its effect. Talk to your doctor about this.
Interaction between Alcohol and Olmezest Beta 25 Tablet ER
Consumption of alcohol and Olmezest Beta 25 Tablet ER together may have severe effects on your health.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Benicar (olmesartan medoxomil)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 507
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 169-173
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lopressor (metoprolol tartrate)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 148-149
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 847-850